Education
About Us
Working with TipRanks
Follow Us
Vectus Biosystems Limited (AU:VBS)
:VBS
VBS Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.28
Previous CloseN/A
Volume32.26K
Average Volume (3M)49.00
Market Cap
AU$4.26M
Enterprise ValueAU$3.32M
Total Cash (Recent Filing)AU$9.99K
Total Debt (Recent Filing)AU$1.90M
Price to Earnings (P/E)―
Beta-0.57
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding53,278,313
10 Day Avg. Volume76
30 Day Avg. Volume49
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)215198.48
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Vectus Biosystems Limited News
PremiumCompany Announcements
Vectus Biosystems Expands Share Base Through Employee Incentive Plan
PremiumCompany Announcements
Vectus Biosystems Expands ASX Quotation with New Securities
PremiumCompany Announcements
Vectus Biosystems Reports Decline in Half-Year Financial Results
PremiumCompany Announcements
Vectus Biosystems Strengthens Board with New Appointment
PremiumCompany Announcements
Vectus Biosystems Gains Strong Shareholder Support
PremiumCompany Announcements
Vectus Biosystems Advances Drug Trials and Commercialization
PremiumCompany Announcements
Vectus Biosystems Advances Drug Portfolio and Seeks Partnerships---
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.07 and its highest was AU$0.28 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$4.26M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Aug 27, 2025 which is in 123 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Feb 21, 2025. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.021.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 53,278,313 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
---
Vectus Biosystems Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:VBS Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.90%
12-Months-Change
Fundamentals
Return on Equity
-163.00%
Trailing 12-Months
Asset Growth
-61.52%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
---
Technical Analysis
Biotron Limited
―
Paradigm Biopharmaceuticals Ltd.
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Medical Developments International Limited
―
---